- Home
- BRTX vs TOVX Comparison
BRTX vs TOVX Comparison
Compare BRTX & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRTX | TOVX |
|---|---|---|
| Founded | 1997 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 6.4M |
| IPO Year | 2015 | 2012 |
Fundamental Metrics
Financial Performance| Metric | BRTX | TOVX |
|---|---|---|
| Price | $0.30 | $0.20 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.5M | ★ 8.8M |
| Earning Date | 03-26-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $81,000.00 | N/A |
| Revenue This Year | $24.64 | N/A |
| Revenue Next Year | $287.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.19 | $0.16 |
| 52 Week High | $2.04 | $1.50 |
Technical Indicators
Market Signals| Indicator | BRTX | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 43.49 | 52.78 |
| Support Level | $0.20 | $0.20 |
| Resistance Level | $1.18 | $0.26 |
| Average True Range (ATR) | 0.03 | 0.02 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 80.48 | 28.31 |
Price Performance
Historical ComparisonAbout BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.